PTC Therapeutics Inc - Company Profile

Powered by

All the data and insights you need on PTC Therapeutics Inc in one report.

  • Save hours of research time and resources with
    our up-to-date PTC Therapeutics Inc Strategy Report

  • Understand PTC Therapeutics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company's pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. It operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

Gain a 360-degree view of PTC Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of PTC Therapeutics Inc and make more informed decisions for your business Find out more
Headquarters United States of America

Address 500 Warren Corporate Center Drive, New Jersey, 07059


Telephone 1 908 2227000

No of Employees 988

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange PTCT (NASD)

Revenue (2022) $937.8M 34.2% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -12.1% (2022 vs 2021)

Market Cap* $2.8B

Net Profit Margin (2022) XYZ 16.5% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

PTC Therapeutics Inc premium industry data and analytics

140+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for PTC Therapeutics Inc’s relevant decision makers and contact details.

120+

Clinical Trials

Determine PTC Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

110+

Catalyst Calendar

Proactively evaluate PTC Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Pipeline Drugs

Identify which of PTC Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

11+

Sales & Consensus Forecasts

Understand the current and future drug revenue for PTC Therapeutics Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

8

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Marketed Drugs

Understand PTC Therapeutics Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on PTC Therapeutics Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Translarna (Ataluren): Duchenne Muscular Dystrophy Evrysdi
Emflaza (Deflazacort): Duchenne Muscular Dystrophy Translarna
Waylivra (Volanesorsen): Familial Chylomicronemia Syndrome Emflaza
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand PTC Therapeutics Inc portfolio and identify potential areas for collaboration Understand PTC Therapeutics Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Regulatory Approval In May, the company announced that the FDA accepted the Biologics License Application for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.
2023 Contracts/Agreements In October, the company entered into an agreement with Royalty Pharma to monetize up to US$1.5 billion of the royalty stream for the spinal muscular atrophy drug Evrysdi (risdiplam).
2022 Financing Agreements In October, the company signed a strategic financing partnership worth up to US$1 billion with funds managed by Blackstone to back the development of innovative product pipeline.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters PTC Therapeutics Inc Astellas Pharma Inc Daiichi Sankyo Co Ltd Biogen Inc Alnylam Pharmaceuticals Inc
Headquarters United States of America Japan Japan United States of America United States of America
City Warren Chuo-Ku Chuo-Ku Cambridge Cambridge
State/Province New Jersey Tokyo Tokyo Massachusetts Massachusetts
No. of Employees 988 14,484 17,435 7,570 2,100
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Michael Schmertzler Chairman Executive Board 2004 71
Matthew B. Klein, M.D. Chief Executive Officer; Director Executive Board 2023 51
Pierre Gravier Chief Financial Officer Senior Management 2023 -
Christine Utter Senior Vice President; Chief Accounting Officer; Head - People Services Senior Management 2019 45
Mark E. Boulding Chief Legal Officer; Executive Vice President Senior Management 2012 62
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into PTC Therapeutics Inc key executives to enhance your sales strategy Gain insight into PTC Therapeutics Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer